ClinicalTrials.gg
CompletedNCT04795479Updated Sep 14, 2021

T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy Volunteers

A Phase 1 interventional study of Relacorilant and Placebo to relacorilant in Healthy, sponsored by Corcept Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-09-14.

Sponsored by Corcept Therapeutics · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2021, 5 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This dedicated T/QT study will investigate the effect of relacorilant on cardiac repolarization in healthy participants.

Read the detailed description

This four-period crossover study with 12 treatment sequences includes relacorilant administered at therapeutic (400 mg once daily [QD]) and supra-therapeutic (800 mg QD) doses, placebo for relacorilant as a negative control, and oral moxifloxacin as a positive control. The positive control will serve to determine the sensitivity of the assay to detect small increases from baseline in the QTc interval. Each of the four treatment periods will last 5 days with a washout of at least 10 days between periods. Relacorilant and placebo to relacorilant will be administered double-blind; moxifloxacin will be administered open label.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Corcept Therapeutics is the lead sponsor of 73 studies on the registry; 3 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 9 (28%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant with a ≥18.0 kg/m\^2 and ≤30.0 kg/m\^2 at screening
  • No abnormal findings with the physical examination, medical/surgical/medication history, vital signs, or clinical laboratory assessments and adequate cardiac conduction by (ECG) without evidence of first-, second- or third-degree atrioventricular block
  • Female participants of with a negative serum pregnancy test at screening and urine pregnancy test on Day -1 of Period 1
  • All male participants agree to use condom to prevent exposure to partner; male participants with female partner of childbearing potential to use a second method of
  • Female participants of childbearing potential agree to use the highly effective contraception of low user dependency
  • Participant is willing and able to comply with all study procedures and restrictions
  • Participant understands the study procedures and agrees to participate by providing written .

Exclusion criteria

Exclusion Criteria:

  • Participant with history or presence of any cardiovascular, pulmonary, respiratory, hepatic, renal, hematological, endocrine, immunologic, dermatologic, neurological, psychiatric disease or disorder or any uncontrolled medical illness which in the opinion of the investigator would jeopardize the safety of the participant, interfere with study assessments, or impact the validity of the study results
  • Participant with a history or family history of additional risk factors for Torsade de Pointe (TdP)
  • Participant with a marked prolongation of intervals, including >450 milliseconds (msec), PR >200 msec, or QRS >120 msec
  • Participant with resting heart rate of \<45beats per minute (bpm) or >100 bpm
  • Participant with clinically significant abnormal ECG results
  • Participant who uses medications that could prolong the QT/QTc interval
  • Participant taking medications/dietary supplements that are highly dependent on cytochrome (CYP)3A for clearance and cannot undergo dose modification upon co-administration with strong inhibitors
  • Participant using any strong CYP3A inhibitor/inducer or any other medications prohibited per protocol
  • Participant who is receiving testosterone within 40 days prior to study start
  • Participant with a positive result for (HIV) antibody, surface antigen, or antibody
  • Participant with a positive test result for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) viral RNA test, either asymptomatic or present with symptoms of Coronavirus disease 2019 (COVID-19)
  • Participant who has travelled abroad within 3 months prior to the screening visit or plans to travel abroad during the study
  • Participant who has had a major surgery within the last 28 days prior to Screening
  • Participant who received any product within 30 days prior to Screening
  • Participant who has a known or suspected allergy, or sensitivity to study products, or any of its ingredient(s), or to moxifloxacin
  • Intolerance to repeated venipuncture or inability to swallow capsules
  • Donation of blood within 56 days or plasma within 14 days prior to Screening or plans to donate during the entire study period
  • Positive alcohol test and/or positive drugs of abuse screen or reports of a history of substance or alcohol abuse within 1 year prior to Screening
  • Female participant who is pregnant, breastfeeding, or is planning to become pregnant during the entire study period
  • Male participant with pregnant partner.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Treatment Sequence 1

    Participants will receive relacorilant 400 mg once daily (QD) for 5 days in Period 1, followed by relacorilant 800 mg QD for 5 days in Period 2, followed by placebo to relacorilant QD for 5 days in Period 3, followed by placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 4. Treatment periods will be separated by a washout of at least 10 days.

    Drug: Relacorilant · Drug: Placebo to relacorilant · Drug: Moxifloxacin

  • Experimental
    Treatment Sequence 2

    Participants will receive relacorilant 800 mg QD for 5 days in Period 1, followed by placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 2, followed by relacorilant 400 mg QD for 5 days in Period 3, followed by placebo to relacorilant QD for 5 days in Period 4. Treatment periods will be separated by a washout of at least 10 days.

    Drug: Relacorilant · Drug: Placebo to relacorilant · Drug: Moxifloxacin

  • Experimental
    Treatment Sequence 3

    Participants will receive placebo to relacorilant QD for 5 days in Period 1, followed by relacorilant 400 mg QD for 5 days in Period 2, followed by placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 3, followed by relacorilant 800 mg QD for 5 days in Period 4. Treatment periods will be separated by a washout of at least 10 days.

    Drug: Relacorilant · Drug: Placebo to relacorilant · Drug: Moxifloxacin

  • Experimental
    Treatment Sequence 4

    Participants will receive relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 1, followed by placebo to relacorilant QD for 5 days in Period 2, followed by relacorilant 800 mg QD for 5 days in Period 3, followed by relacorilant 400 mg QD for 5 days in Period 4. Treatment periods will be separated by a washout of at least 10 days.

    Drug: Relacorilant · Drug: Placebo to relacorilant · Drug: Moxifloxacin

  • Experimental
    Treatment Sequence 5

    Participants will receive relacorilant 800 mg QD for 5 days in Period 1, followed by placebo to relacorilant QD for 5 days in Period 2, followed by relacorilant 400 mg QD for 5 days in Period 3, followed by relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 4. Treatment periods will be separated by a washout of at least 10 days.

    Drug: Relacorilant · Drug: Placebo to relacorilant · Drug: Moxifloxacin

  • Experimental
    Treatment Sequence 6

    Participants will receive placebo to relacorilant QD for 5 days in Period 1, followed by placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 2, followed by relacorilant 800 mg QD for 5 days in Period 3, followed by relacorilant 400 mg QD for 5 days in Period 4. Treatment periods will be separated by a washout of at least 10 days.

    Drug: Relacorilant · Drug: Placebo to relacorilant · Drug: Moxifloxacin

  • Experimental
    Treatment Sequence 7

    Participants will receive relacorilant 400 mg QD for 5 days in Period 1, followed by relacorilant 800 mg QD for 5 days in Period 2, followed by placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 3, followed by placebo to relacorilant QD for 5 days in Period 4. Treatment periods will be separated by a washout of at least 10 days.

    Drug: Relacorilant · Drug: Placebo to relacorilant · Drug: Moxifloxacin

  • Experimental
    Treatment Sequence 8

    Participants will receive placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 1, followed by relacorilant 400 mg QD for 5 days in Period 2, followed by placebo to relacorilant QD for 5 days in Period 3, followed by relacorilant 800 mg QD for 5 days in Period 4. Treatment periods will be separated by a washout of at least 10 days.

    Drug: Relacorilant · Drug: Placebo to relacorilant · Drug: Moxifloxacin

  • Experimental
    Treatment Sequence 9

    Participants will receive placebo to relacorilant QD for 5 days in Period 1, followed by relacorilant 400 mg QD for 5 days in Period 2, followed by relacorilant 800 mg QD for 5 days in Period 3, followed by placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 4. Treatment periods will be separated by a washout of at least 10 days.

    Drug: Relacorilant · Drug: Placebo to relacorilant · Drug: Moxifloxacin

  • Experimental
    Treatment Sequence 10

    Participants will receive relacorilant 400 mg QD for 5 days in Period 1, followed by placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 2, followed by placebo to relacorilant QD for 5 days in Period 3, followed by relacorilant 800 mg QD for 5 days in Period 4. Treatment periods will be separated by a washout of at least 10 days.

    Drug: Relacorilant · Drug: Placebo to relacorilant · Drug: Moxifloxacin

  • Experimental
    Treatment Sequence 11

    Participants will receive relacorilant 800 mg QD for 5 days in Period 1, followed by placebo to relacorilant QD for 5 days in Period 2, followed by placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 3, followed by relacorilant 400 mg QD for 5 days in Period 4. Treatment periods will be separated by a washout of at least 10 days.

    Drug: Relacorilant · Drug: Placebo to relacorilant · Drug: Moxifloxacin

  • Experimental
    Treatment Sequence 12

    Participants will receive placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 1, followed by relacorilant 800 mg QD for 5 days in Period 2, followed by relacorilant 400 mg QD for 5 days in Period 3, followed by placebo to relacorilant QD for 5 days in Period 4. Treatment periods will be separated by a washout of at least 10 days.

    Drug: Relacorilant · Drug: Placebo to relacorilant · Drug: Moxifloxacin

Interventions

  • Relacorilant 400 mg (therapeutic dose) or 800 mg (supra-therapeutic dose) capsule by mouth once daily

    Also known as: CORT125134

  • DrugPlacebo to relacorilant

    Placebo to relacorilant capsule by mouth once daily

  • Moxifloxacin 400 mg tablet by mouth

06

What researchers measure

Primary outcomes

  1. Placebo-corrected Change from Baseline in Cardiac QT Interval Corrected by Fridericia's Formula (QTcF)

    Time frame: Before dosing (Baseline) through 24 hours after the final dose on Day 5 in each treatment period

Secondary outcomes

  1. Change from Baseline in Cardiac QTcF

    Time frame: Before dosing (Baseline) through 24 hours after the final dose on Day 5 in each treatment period

  2. Change from Baseline in Heart Rate (HR)

    Time frame: Before dosing (Baseline) through 24 hours after the final dose on Day 5 in each treatment period

  3. Placebo-corrected Change from Baseline in HR

    Time frame: Before dosing (Baseline) through 24 hours after the final dose on Day 5 in each treatment period

  4. Change from Baseline in Cardiac PR Interval

    Time frame: Before dosing (Baseline) through 24 hours after the final dose on Day 5 in each treatment period

  5. Placebo-corrected Change from Baseline in Cardiac PR Interval

    Time frame: Before dosing (Baseline) through 24 hours after the final dose on Day 5 in each treatment period

  6. Change from Baseline in Cardiac QRS Intervals

    Time frame: Before dosing (Baseline) through 24 hours after the final dose on Day 5 in each treatment period

  7. Placebo-corrected Change from Baseline in Cardiac QRS Intervals

    Time frame: Before dosing (Baseline) through 24 hours after the final dose on Day 5 in each treatment period

  8. Number of Participants with a Categorical Outlier in QTcF

    Time frame: Up to Day 6 in each treatment period (through 24 hours after the final dose on Day 5 in each treatment period)

  9. Number of Participants with a Categorical Outlier in HR

    Time frame: Up to Day 6 in each treatment period (through 24 hours after the final dose on Day 5 in each treatment period)

  10. Number of Participants with a Categorical Outlier in PR Interval

    Time frame: Up to Day 6 in each treatment period (through 24 hours after the final dose on Day 5 in each treatment period)

  11. Number of Participants with a Categorical Outlier in QRS Intervals

    Time frame: Up to Day 6 in each treatment period (through 24 hours after the final dose on Day 5 in each treatment period)

  12. Number of Participants with a Treatment-emergent Change of T-wave Morphology

    Time frame: Up to Day 6 in each treatment period (through 24 hours after the final dose on Day 5 in each treatment period)

  13. Number of Participants with a Treatment-emergent Presence of U-waves

    Time frame: Up to Day 6 in each treatment period (through 24 hours after the final dose on Day 5 in each treatment period)

  14. Maximum Plasma Concentration (Cmax) of Relacorilant, Metabolites of Relacorilant, and Moxifloxacin

    Time frame: Before dosing and at 0.5, 1, 1,5, 2, 3, 4, 6, 8, 12, 16, and 24 hours after dosing on Day 1 and 5 in each treatment period

  15. Time to Reach Cmax (Tmax) of Plasma Relacorilant, Metabolites of Relacorilant, and Moxifloxacin

    Time frame: Before dosing and at 0.5, 1, 1,5, 2, 3, 4, 6, 8, 12, 16, and 24 hours after dosing on Day 1 and 5 in each treatment period

  16. Minimum Plasma Concentration (Cmin) of Relacorilant, Metabolites of Relacorilant, and Moxifloxacin

    Time frame: Before dosing on Day 5 of each treatment period

  17. Area Under the Plasma-concentration Curve from Time Zero to Time of Last Measurable Concentration (AUClast) of Relacorilant, Metabolites of Relacorilant, and Moxifloxacin

    Time frame: Before dosing and at 0.5, 1, 1,5, 2, 3, 4, 6, 8, 12, 16, and 24 hours after dosing on Day 1 and 5 in each treatment period

  18. Area Under the Plasma-concentration Curve from Time Zero to 24 Hours Postdose (AUC0-24) of Relacorilant, Metabolites of Relacorilant, and Moxifloxacin

    Time frame: Before dosing and at 0.5, 1, 1,5, 2, 3, 4, 6, 8, 12, 16, and 24 hours after dosing on Day 1 and 5 in each treatment period

  19. Number of Participants with One or More Adverse Events

    Time frame: Up to Day 6 in each treatment period (up to 51 days)

  20. Number of Participants Discontinued From Study Treatment due to an Adverse Event

    Time frame: Up to Day 6 of each treatment period (up to 51 days)

07

Study locations

1 site
  • Single Site
    Springfield, Missouri 65802, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2021 to primary completion in May 2021, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2021
First posted
Mar 12, 2021
StartActual
Jan 22, 2021
Primary completionActual
May 17, 2021
CompletionActual
Jul 13, 2021
Last update
Sep 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04795479
Responsible party
Sponsor
First posted
Mar 12, 2021
Start date
Jan 22, 2021
Primary completion
May 17, 2021
Completion
Jul 13, 2021
Last update
Sep 14, 2021

Study contacts

Joseph Custodio, PhD
study director · Corcept Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Relacorilant

Start the discussion